Granules India Limited — Updates, 10-04-2025: Press Release

Granules India Limited has successfully closed the acquisition of Senn Chemicals AG, a Swiss-based CDMO specializing in peptide development and manufacturing. This strategic move enhances Granules' capabilities in the fast-growing peptide therapeutics sector, marking a significant evolution towards a science- and innovation-led organization. Through its subsidiary, Granules Peptides Private Limited, Granules acquired 100% equity of Senn Chemicals, leveraging its expertise in Liquid-Phase and Solid-Phase Peptide Synthesis.

The acquisition is poised to accelerate the development and manufacturing of peptide-based APIs, addressing increasing demand in therapeutic areas such as anti-diabetic and anti-obesity treatments. Granules aims to integrate Senn's specialized knowledge and established customer relationships to expand its global footprint and enhance its position in the CDMO space. With joint development activities already underway, this acquisition presents promising opportunities for growth and innovation in Granules' product portfolio.